pmjТихоокеанский медицинский журналPacific Medical Journal1609-1175TGMU10.34215/1609-1175-2025-4-63-69pmj-3020Research ArticleОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯORIGINAL RESEARCHESПоиск потенциальных анксиолитиков среди селективных ингибиторов карбоангидразы II типаResearch into novel anxiolytics among selective carbonic anhydrase II inhibitorsЛазарянцО. Э.LazariantsO. E.

 Ярославль, 

Yaroslavl

ФедоровВ. Н.FedorovV. N.

 Ярославль 

Yaroslavl

ШетневА. А.ShetnevA. A.

Ярославль 

Московская область, Долгопрудный

Yaroslavl 

Moscow 

СапегинА. В.SapeginA. V.

 Санкт-Петербург

Saint Petersburg

https://orcid.org/0000-0002-3176-2716СулеймановС. Ш.SuleymanovS. Sh.

Сулейманов Салават Шeйхович – д-р мед. наук, профессор, генеральный директор

680000, Хабаровск, ул. Комсомольская, 104); ORCID: 

Salavat S. Suleymanov, Dr. Sci. (Med.), Prof., General Director

104 Komsomolskaya str., Khabarovsk, 680000, Russia

suleymanov-sh@mail.ruЯрославский государственный медицинский университет; Ярославский государственный педагогический университетРоссияYaroslavl State Medical University; Yaroslavl State Pedagogical UniversityRussian FederationЯрославский государственный педагогический университет; Московский физико-технический институтРоссияYaroslavl State Pedagogical University; Moscow Institute of Physics and TechnologyRussian FederationСанкт-Петербургский государственный университетРоссияSaint Petersburg State UniversityRussian FederationРоссийско-японский медицинский центрРоссияRussian-Japanese Medical CenterRussian Federation202515022026046369Copyright © Лазарянц О.Э., Федоров В.Н., Шетнев А.А., Сапегин А.В., Сулейманов С.Ш., 20262026Лазарянц О.Э., Федоров В.Н., Шетнев А.А., Сапегин А.В., Сулейманов С.Ш.Lazariants O.E., Fedorov V.N., Shetnev A.A., Sapegin A.V., Suleymanov S.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.tmj-vgmu.ru/jour/article/view/3020

Цель: поиск новых анксиолитиков среди селективных ингибиторов карбоангидразы II типа.Материалы и методы. Материалами исследования являются 9 новых селективных ингибиторов карбоангидразы II типа (ИКА II) – производные сульфонамидов с лабораторными шифрами В1–3, В10–13, В18, В24. В данной работе использовали методики «Открытое поле», «Приподнятый крестообразный лабиринт» и «Подвешивание за хвост». Исследования проводили на двух видах животных: мыши и крысы. Статистическая обработка проводилась при помощи программы Microsoft Excel и «Биостатистика». Результаты. Соединение В24 в экспериментах и на крысах, и на мышах обладает анксиолитической и антидепрессивной активностью, а также повышает когнитивные функции животных. Потенциально анксиолитическим действием обладает соединение В10, В12 и В18, а антидепрессивной активностью – В13. Заключение. Результаты исследования показали, что новые препараты среди селективных ингибиторов карбоангидразы II типа обладают анксиолитической, антидепрессивной активностью и повышают когнитивные функции у животных.

Objective. To identify new anxiolytics among selective carbonic anhydrase II inhibitors. Materials and methods. The study involved nine new selective carbonic anhydrase II (CAII) inhibitors, which are sulfonamide derivatives with laboratory codes B1–3, B10–13, B18, and B24. The open field, elevated plus maze, and tail suspension tests were used. Two types of animals were examined: mice and rats. Statistical processing was performed using Microsoft Excel and Biostatistics software.Results. Both in experiments on rats and mice, compound B24 exhibits anxiolytic and antidepressant activity, while also enhancing the cognitive functions of animals. Compounds B10, B12, and B18 potentially possess anxiolytic effects, while B13 exhibits antidepressant activity. Сonclusion. The study results indicate that new drugs from selective carbonic anhydrase II inhibitors possess anxiolytic and antidepressant activity while improving cognitive functions in animals.

ингибиторы карбоангидразы II типаанксиолитикитранквилизаторыповеденческие реакцииcarbonic anhydrase II inhibitorsanxiolyticstranquilizersbehavioral responsesНаучное исследование выполнено за счет гранта в форме субсидий (соглашение № 25НП/2024).ReferencesZhao H, Zhou M, Liu Y, Jiang J, Wang Y. Recent advances in anxiety disorders: Focus on animal models and pathological mechanisms. Animal Model Exp Med. 2023;6(6):559–72. doi: 10.1002/ame2.12360Zhao H, Zhou M, Liu Y, Jiang J, Wang Y. Recent advances in anxiety disorders: Focus on animal models and pathological mechanisms. Animal Model Exp Med. 2023;6(6):559–72. doi: 10.1002/ame2.12360COVID-19 Mental Disorders Collaborators. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. Lancet. 2021;398(10312):1700–12. doi: 10.1016/S0140-6736(21)02143-7COVID-19 Mental Disorders Collaborators. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. Lancet. 2021;398(10312):1700–12. doi: 10.1016/S0140-6736(21)02143-7Penninx BW, Pine DS, Holmes EA, Reif A. Anxiety disorders. Lancet. 2021;397(10277):914–27. doi: 10.1016/S0140-6736(21)00359-7Penninx BW, Pine DS, Holmes EA, Reif A. Anxiety disorders. Lancet. 2021;397(10277):914–27. doi: 10.1016/S0140-6736(21)00359-7Ly C, Greb AC, Cameron LP, Cameron LP, Wong JM, Barragan EV, Wilson PC, Burbach KF, Soltanzadeh Zarandi S, Sood A, Paddy MR, Duim WC, Dennis MY, McAllister AK, OriMcKenney KM, Gray JA, Olson DE. Psychedelics promote structural and functional neural plasticity. Cell Rep. 2018;23(11):3170–82. doi: 10.1016/j.celrep.2018.05.022Ly C, Greb AC, Cameron LP, Cameron LP, Wong JM, Barragan EV, Wilson PC, Burbach KF, Soltanzadeh Zarandi S, Sood A, Paddy MR, Duim WC, Dennis MY, McAllister AK, OriMcKenney KM, Gray JA, Olson DE. Psychedelics promote structural and functional neural plasticity. Cell Rep. 2018;23(11):3170–82. doi: 10.1016/j.celrep.2018.05.022Javaid SF, Hashim IJ, Hashim MJ, Stip E, Samad MA, Ahbabi AA.Epidemiology of anxiety disorders: Global burden and sociodemographic associations. Middle East Current Psychiatry. 2023;30(1):44. doi: 10.1186/s43045-023-00315-3Javaid SF, Hashim IJ, Hashim MJ, Stip E, Samad MA, Ahbabi AA.Epidemiology of anxiety disorders: Global burden and sociodemographic associations. Middle East Current Psychiatry. 2023;30(1):44. doi: 10.1186/s43045-023-00315-3Léonard C, Charriau-Perret A, Debaty G, Belle L, Ricard C, Sanchez C, Dupré PM, Panoff G, Bougerol T, Viglino D, Blancher M; Northern French-Alps Emergency Network (“RENAU”). Survivors of avalanche accidents: posttraumatic stress disorder symptoms and quality of life: A multicentre study. Scand J Trauma Resusc Emerg Med. 2021;29(1):96. doi:10.1186/s13049-021-00912-3Léonard C, Charriau-Perret A, Debaty G, Belle L, Ricard C, Sanchez C, Dupré PM, Panoff G, Bougerol T, Viglino D, Blancher M; Northern French-Alps Emergency Network (“RENAU”). Survivors of avalanche accidents: posttraumatic stress disorder symptoms and quality of life: A multicentre study. Scand J Trauma Resusc Emerg Med. 2021;29(1):96. doi:10.1186/s13049-021-00912-3Ren L, Fan Y, Wu W, Qian Y, He M, Li X, Wang Y, Yang Y, Wen X, Zhang R, Li C, Chen X, Hu J. Anxiety disorders: Treatments, models, and circuitry mechanisms. Eur J Pharmacol. 2024;983:176994. doi: 10.1016/j.ejphar.2024.176994Ren L, Fan Y, Wu W, Qian Y, He M, Li X, Wang Y, Yang Y, Wen X, Zhang R, Li C, Chen X, Hu J. Anxiety disorders: Treatments, models, and circuitry mechanisms. Eur J Pharmacol. 2024;983:176994. doi: 10.1016/j.ejphar.2024.176994Capiau A, Huys L, van Poelgeest E, van der Velde N, Petrovic M, Somers A; EuGMS Task, Finish Group on FRIDs. Therapeutic dilemmas with benzodiazepines and Z-drugs: Insomnia and anxiety disorders versus increased fall risk: A clinical review. Eur Geriatr Med. 2023;14(4):697–708. doi: 10.1007/s41999-022-00731-4Capiau A, Huys L, van Poelgeest E, van der Velde N, Petrovic M, Somers A; EuGMS Task, Finish Group on FRIDs. Therapeutic dilemmas with benzodiazepines and Z-drugs: Insomnia and anxiety disorders versus increased fall risk: A clinical review. Eur Geriatr Med. 2023;14(4):697–708. doi: 10.1007/s41999-022-00731-4Goldschen-Ohm MP. Benzodiazepine modulation of GABAA receptors: A mechanistic perspective. Biomolecules. 2022;12(12):1784. doi: 10.3390/biom12121784AGoldschen-Ohm MP. Benzodiazepine modulation of GABAA receptors: A mechanistic perspective. Biomolecules. 2022;12(12):1784. doi: 10.3390/biom12121784AKnight P, Chellian R, Wilson R, Behnood-Rod A, Panunzio S, Bruijnzeel AW. Sex differences in the elevated plus-maze test and large open field test in adult Wistar rats. Pharmacol Biochem Behav. 2021;204:173168. doi: 10.1016/j.pbb.2021.173168Knight P, Chellian R, Wilson R, Behnood-Rod A, Panunzio S, Bruijnzeel AW. Sex differences in the elevated plus-maze test and large open field test in adult Wistar rats. Pharmacol Biochem Behav. 2021;204:173168. doi: 10.1016/j.pbb.2021.173168Can A, Dao DT, Terrillion CE, Piantadosi SC, Bhat S, Gould TD. The tail suspension test. J Vis Exp. 2012;(59):e3769. doi: 10.3791/3769Can A, Dao DT, Terrillion CE, Piantadosi SC, Bhat S, Gould TD. The tail suspension test. J Vis Exp. 2012;(59):e3769. doi: 10.3791/3769Supuran CT. Coumarin carbonic anhydrase inhibitors from natural sources. J Enzyme Inhib Med Chem. 2020;35(1):1462–70. doi: 10.1080/14756366.2020.1788009Supuran CT. Coumarin carbonic anhydrase inhibitors from natural sources. J Enzyme Inhib Med Chem. 2020;35(1):1462–70. doi: 10.1080/14756366.2020.1788009Mehrhoff EA, Booher WC, Hutchinson J, Schumacher G, Borski C, Lowry CA, Hoeffer CA, Ehringer MA. Diazepam effects on anxiety-related defensive behavior of male and female high and low open-field activity inbred mouse strains. Physiol Behav. 2023;271:114343. doi: 10.1016/j.physbeh.2023.114343Mehrhoff EA, Booher WC, Hutchinson J, Schumacher G, Borski C, Lowry CA, Hoeffer CA, Ehringer MA. Diazepam effects on anxiety-related defensive behavior of male and female high and low open-field activity inbred mouse strains. Physiol Behav. 2023;271:114343. doi: 10.1016/j.physbeh.2023.114343Pentkowski NS, Rogge-Obando KK, Donaldson TN, Bouquin SJ, Clark BJ. Anxiety and Alzheimer's disease: Behavioral analysis and neural basis in rodent models of Alzheimer's-related neuropathology. Neurosci Biobehav Rev. 2021;127:647–58. doi: 10.1016/j.neubiorev.2021.05.005Pentkowski NS, Rogge-Obando KK, Donaldson TN, Bouquin SJ, Clark BJ. Anxiety and Alzheimer's disease: Behavioral analysis and neural basis in rodent models of Alzheimer's-related neuropathology. Neurosci Biobehav Rev. 2021;127:647–58. doi: 10.1016/j.neubiorev.2021.05.005

The authors declare that there are no conflicts of interest present.